Business Wire

Seqirus Announces Next Major Advancement in Cell-Based Influenza Vaccine Technology

HOLLY SPRINGS, N.C.--(BUSINESS WIRE)--Seqirus, a leading innovator in influenza vaccines and pandemic preparedness, today announced the next major advancement in the use of cell-based technology at ...
FiercePharma

CSL Seqirus scores $30M government contract to produce and test avian flu vaccine candidate

CSL Seqirus, one of the world’s top flu vaccine companies, scored a $30.1 million deal from the Biomedical Advanced Research and Development Authority (BARDA) to deliver an avian flu vaccine candidate ...
Yahoo Finance

Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
FiercePharma

CSL's Seqirus delivers record number of flu vaccines despite pandemic, and now it's eyeing next-gen mRNA shots

Despite a global pandemic and social distancing measures threatening to hamper influenza vaccinations last season, CSL’s Seqirus managed to deliver a record number of flu shots—and it’s preparing to ...
Nasdaq

Seqirus Publishes New Real-World Evidence (RWE) on Relative Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older in Vaccines

SUMMIT, N.J., Sept. 21, 2020 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, today announced the publication of new real-world evidence (RWE) that demonstrated an MF59® adjuvanted, ...
Yahoo

Will bird flu be the next pandemic? Vaccines are prepped, just in case.

Add Yahoo as a preferred source to see more of our stories on Google. HOLLY SPRINGS, N.C. ‒ A quiet effort to prevent the next global pandemic began rolling off an assembly line this summer behind the ...
NJBIZ

Seqirus’ battle against influenza now $156M stronger

Summit-based Seqirus is ramping up its fight against influenza with the completion of a $156 million expansion of its manufacturing facility in North Carolina. The influenza-focused vaccine company ...
Business Wire

Seqirus Begins Shipping 2017-2018 Influenza Vaccines to the U.S. Market

Seqirus is now shipping its portfolio of over 50 million doses of influenza vaccines to the U.S. market in preparation for the upcoming 2017-2018 influenza season. Seqirus utilizes both egg and ...
Medindia

Seqirus Announces U.S. FDA Approval of Expanded Age Indication of Its Cell-Based Quadrivalent Influenza Vaccine for People Two Years of Age and Older

SUMMIT, N.J., March 5, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, today announced that the U.S. Food and Drug Administration (FDA) has approved FLUCELVAX ® QUADRIVALENT ...
Nasdaq

Seqirus Presents New Real-World Evidence Demonstrating Effectiveness of Cell-Based and Adjuvanted Seasonal Influenza Vaccines at IDWeek 2021

SUMMIT, N.J., Sept. 29, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX: CSL), today announced data supporting the effectiveness of both ...
Forbes

For Seqirus, mRNA Offers The Next Big Breakthrough In Flu Vaccines

Doses of vaccine in the packaging system. Spare a bit of sympathy for our flu vaccine makers. Chris Larkins, SVP of Global Operations at Seqirus. “For flu, chasing variants is such a challenge in ...
Healio

Seqirus makes plans to transition to cell-based flu vaccine

Please provide your email address to receive an email when new articles are posted on . Seqirus announced plans manufacture its influenza vaccine for the 2019-2020 season using an exclusively ...